利福喷丁和利福平在涂阳肺结核患者中的疗效及安全性比较

摘要

目的 比较利福喷丁和利福平在涂阳肺结核患者中的临床治疗效果及安全性.方法 选取2015年6月～2016年7月常山县人民医院诊治的涂阳肺结核患者80 例,随机分为对照组(n =40)和观察组(n =40).对照组采用利福平治疗,观察组采用利福喷丁治疗,比较2 组治疗效果及并发症发生情况.结果 观察组治疗6 个月后痰涂片转阴、空洞闭合及病灶吸收比例显著高于对照组( P< 0.05);2组治疗前的外周血T淋巴细胞亚群CD3+、CD4+、CD8+水平差异无统计学意义;观察组治疗后外周血T淋巴细胞亚群CD3+、CD4+、CD8+水平显著高于对照组( P< 0.05);观察组治疗后并发症发生率为7.5％,显著低于对照组的17.5％( P< 0.05).结论 与利福平治疗相比,涂阳肺结核患者采用利福喷丁治疗效果理想,能改善机体免疫功能,并发症发生率较低.%Objective To compare the clinical therapeutic effect and safety of rifapentine and rifampicin in smear positive pulmonary tuberculosis patients.Methods A total of 80 patients with smear positive pulmonary tuberculosis were chosen in Changshan People's Hospital from June 2015 to July 2016,the patients were randomly divided into control group(n=40)and observation group(n=40).The control group used rifampicin treatment,observation group were treated with rifapentine therapy,the therapeutic effect and incidence of complications between two groups were compared.Results Proportion of the sputum smear negative,cavity closure and lesions absorption in the observation group after 6 months of treatment were significantly higher than those in the control group; peripheral blood T lymphocyte subsets CD3+,CD4+,CD8+ levels in two groups before treatment had no statistically significant differences; peripheral blood of T lymphocyte subsets CD3+,CD4+,CD8+ levels in the observation group after treatment were significantly higher than those in the control group(P<0.05); incidence of complications in observation group(7.5％)after treatment was significantly lower than that in the control group(17.5％)(P<0.05).Conclusion Compared with rifampicin in treatment of smear positive pulmonary tuberculosis patients,rifapentine has ideal treatment effect,can improve the immune function,low incidence of complications.